PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and ...
Please provide your email address to receive an email when new articles are posted on . A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy ...
DelveInsight's PDE4 Inhibitor Market Report Reveals Significant Growth Through 2034, Led by Arcutis Biotherapeutics, Pfizer, Shionogi, Palisade Bio, UNION Therapeutics, Amgen, and Chiesi Farmaceutici ...
There are currently no FDA-approved treatments for CIAS, a disabling feature of the disease that includes impaired attention, memory, and executive function. The Food and Drug Administration (FDA) has ...
– ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated ...
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of ...
NEW ORLEANS — For the treatment of plaque psoriasis, a novel oral phosphodiesterase-4 (PDE4) inhibitor achieved high rates of response compared with placebo, according to results of a phase 2 clinical ...
Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...
Oral roflumilast (Daliresp) may be an inexpensive and effective treatment option for patients with psoriasis who are candidates for systemic therapy, according to research presented at the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback